Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraventricular 5-Azacytidine and Trastuzumab for Recurrent Posterior Fossa Ependymoma
NCT04958486Phase 1Completed
- Sponsor
- UTHealth Houston
- Start
- Jul 2021
- Primary completion
- Sep 2023
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azacitidine and trastuzumab in ependymoma, sponsored by UTHealth Houston. Primary endpoint: Number of patients with new neurological deficits. Started Jul 2021; status: completed.
02
Drugs
azacitidinetrastuzumab
03
Conditions
ependymoma
Beyond the preview
Go deeper on NCT04958486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958486.